Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden

Acta Oncologica

Volumn 47, Issue 6, 2008, Pages 1029-1036

  Kasteng, Frida ^a,f   Erlanson, Martin ^b   Hagberg, Hans ^c   Kimby, Eva ^d   Relander, Thomas ^e   Lundkvist, Jonas ^a  

^a i3 Innovus   (Sweden)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f NONE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB;

ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFECT; FOLLICULAR LYMPHOMA; HEALTH CARE PERSONNEL; HUMAN; LIFE EXPECTANCY; MAINTENANCE THERAPY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SWEDEN;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; DRUG COSTS; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; REMISSION INDUCTION; SWEDEN; TREATMENT OUTCOME;

EID: 51149091885     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860802120028     Document Type: Article

References (21)

1. Svenska Lymfomregistret Rapport för år 2000-2005 (the Swedish lymphoma registry report 2000-2005), Svenska Lymfomgruppen, Sveriges Onkologiska Centra [Online]. Available from: http://www.ocsyd.lu.se/VP-verksamhet/ Kvalitetsreg/RapportLymfom2000-2005.pdf.
2. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-91.
3. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121-7.
4. Intragumtornchai T, Bunworasate U, Nakorn TN, Rojnuckarin P. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2006;47:1306-14.
5. van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial. Blood 2006;108:3295-301.
6. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725-32.
7. Fisher RI. Overview of Southwest Oncology Group Clinical Trials in non-Hodgkin Lymphoma. S0016. A phase III trial of CHOP vs CHOP+rituximab vs CHOP+iodine131-labeled monoclonal anti-B1 antibody (tositumomab) for treatment of newly diagnosed follicular NHL. Clin Adv Hematol Oncol 2005;3:544-6.
8. Committee for medicinal products for human use postauthorisation summary of positive opinion for Mabthera [Online]. [cited 2007 April]; Available from: www.emea.europa.eu/pdfs/human/opinion/20477106en.pdf.
9. Forstpointner R, Unterhalt M, Dreyling M, Bock HP, Repp R, Wandt H, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006;108:4003-8.
10. Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004;103:4416-23.
11. Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA. Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma - a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005;23:1088-95.
12. EORTC20981: Clinical Study Report - EORTC20981 (M39022) - Chimeric anti-CD20 monoclonal antibody (MabThera) in remission induction and maintenance treatment of relapsed follicular non-Hodgkin's lymphoma: A phase III randomized clinical trial - Intergroup Collaborative Study. Research report 1016350 - December, 2005.
13. Berto P, Lopatriello S, Arcaini L, Del Poeta G, Martellin M, Gargantini L, et al. Costo-efficacia di rituximab nella terapia di mantenimento in soggetti affetti da linfoma non-Hodgkin follicolare refrattario o recidivante. PharmacoEconomics-Italian Research Articles 2007;9:9-19.
14. General guidelines for economic evaluations from the Pharmaceutical Benefits Board (LFNAR 2003:2) [Online]. [cited 2007 April]; Available from: http://www.lfn.se/upload/Foretag/ENG_lfnar2003-eng.pdf.
15. Läkemedelsportalen (Swedish national pharmaceuticals price list) [Online]. [cited 2007 April]; Available from: www.fass.se.
16. Prislista Akademiska sjukhuset i Uppsala (Uppsala University Hospital price list) [Online]. [cited 2007 April]; Available from: www.externt9.lul.se/ svn/uppsala07.xls.
17. Prislista Universitetsjukhuset MAS-Malmö (Malmö University Hospital price list) [Online]. [cited 2007 April]; Available from: www.srvn.org/prislista.htm.
18. KPP-databasen (the national inpatient case-costing database), The Swedish Association of Local Authorities and Regions [Online]. [cited 2007 April]; Available from: stat.skl.se/kppprod/index.htm
19. Martin Erlanson, Norrlands University Hospital, Umeå; Hans Hagberg, Uppsala University Hospital; Uppsala; Eva Kimby, Karolinska University Hospital, Huddinge; Thomas Relander, Lund University Hospital, Lund; [personal communication, April 2007].
20. Utility values in Follicular Lymphoma. Oxford Outcomes Ltd 2005.
21. Persson U, Hjelmgren J. [Health services need knowledge of how the public values health]. Lakartidningen 2003;100:3436-7.